Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | LMNA | P02545 | 4/20 | 0.36 |
| ▸ | CTNNB1 | P35222 | 3/20 | 0.35 |
| ▸ | WNT3A | P56704 | 3/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17349850 | 0.89 | TSHR (0.41) | ALDH1A1LMNACTNNB1WNT3AL3MBTL1 | |
| SCHEMBL17350001 | 0.89 | TSHR (0.37) | ALDH1A1HPGDMEN1KMT2ARAB9A | |
| SCHEMBL17349760 | 0.88 | RAB9A (0.37) | ALDH1A1LMNAL3MBTL1HPGDMEN1 | |
| SCHEMBL17337057 | 0.87 | PRKCB (0.33) | — | |
| SCHEMBL17337052 | 0.87 | PRKCB (0.33) | — | |
| SCHEMBL18957224 | 0.86 | PRKCB (0.34) | — | |
| SCHEMBL18957225 | 0.86 | PRKCB (0.34) | — | |
| SCHEMBL17337350 | 0.86 | PRKCB (0.33) | — | |
| SCHEMBL17337353 | 0.86 | PRKCB (0.33) | — | |
| SCHEMBL17337366 | 0.86 | MTNR1A (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150361107-A1 | ORALLY BIOAVAILABLE BETA-LACTAMASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150361107-A1 | ORALLY BIOAVAILABLE BETA-LACTAMASE INHIBITORS | SI, ALPI, GAA | ALDH1A1 273/4885LMNA 646/4885CTNNB1 323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.